María Jesús
Perugorría Montiel
Universidad del País Vasco/Euskal Herriko Unibertsitatea
Lejona, EspañaPublicaciones en colaboración con investigadores/as de Universidad del País Vasco/Euskal Herriko Unibertsitatea (24)
2024
-
Fibroblast-Derived Lysyl Oxidase Increases Oxidative Phosphorylation and Stemness in Cholangiocarcinoma
Gastroenterology, Vol. 166, Núm. 5, pp. 886-901.e7
-
Heterogeneity, crosstalk, and targeting of cancer-associated fibroblasts in cholangiocarcinoma
Hepatology, Vol. 79, Núm. 4, pp. 941-958
-
m6A Methylated Long Noncoding RNA LOC339803 Regulates Intestinal Inflammatory Response
Advanced Science, Vol. 11, Núm. 13
2023
-
A3907, a systemic ASBT inhibitor, improves cholestasis in mice by multiorgan activity and shows translational relevance to humans
Hepatology (Baltimore, Md.), Vol. 78, Núm. 3, pp. 709-726
-
Inhibition of YTHDF1 by salvianolic acid overcomes gluten-induced intestinal inflammation
Gut
-
Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinoma
Journal of Hepatology, Vol. 79, Núm. 1, pp. 93-108
-
Targeting the Heterogeneous Tumour-Associated Macrophages in Hepatocellular Carcinoma
Cancers, Vol. 15, Núm. 20
2022
-
Cholangiocarcinoma progression depends on the uptake and metabolization of extracellular lipids
Hepatology, Vol. 76, Núm. 6, pp. 1617-1633
-
Genetics, pathobiology and therapeutic opportunities of polycystic liver disease
Nature Reviews Gastroenterology and Hepatology, Vol. 19, Núm. 9, pp. 585-604
-
TREM-2 plays a protective role in cholestasis by acting as a negative regulator of inflammation
Journal of Hepatology, Vol. 77, Núm. 4, pp. 991-1004
-
Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models
Journal of Hepatology, Vol. 77, Núm. 1, pp. 177-190
2021
-
E2F1 and E2F2-mediated repression of CPT2 establishes a lipid-rich tumor-promoting environment
Cancer Research, Vol. 81, Núm. 11, pp. 2874-2887
-
FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted
Journal of Hepatology, Vol. 75, Núm. 2, pp. 363-376
-
Synthetic Conjugates of Ursodeoxycholic Acid Inhibit Cystogenesis in Experimental Models of Polycystic Liver Disease
Hepatology, Vol. 73, Núm. 1, pp. 186-203
-
TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms
Gut, Vol. 70, Núm. 7, pp. 1345-1361
-
Targeting UBC9-mediated protein hyper-SUMOylation in cystic cholangiocytes halts polycystic liver disease in experimental models
Journal of Hepatology, Vol. 74, Núm. 2, pp. 394-406
2020
-
Efficacy and safety of the combination of pravastatin and sorafenib for the treatment of advanced hepatocellular carcinoma (Estahep clinical trial)
Cancers, Vol. 12, Núm. 7, pp. 1-14
-
Proteostasis disturbances and endoplasmic reticulum stress contribute to polycystic liver disease: New therapeutic targets
Liver International, Vol. 40, Núm. 7, pp. 1670-1685
-
Retrospective cohort study: Risk of gastrointestinal cancer in a symptomatic cohort after a complete colonoscopy: Role of faecal immunochemical test
World Journal of Gastroenterology, Vol. 26, Núm. 1, pp. 70-85
2018
-
Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression
Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1864, Núm. 4, pp. 1335-1344